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Abstract
We reported the new biphasic composites of calcium phosphate and mesoporous silica material (CaP@MSi) in the form of
powders and pellets as a potential bone drug delivery system for doxycycline hydrochloride (DOX). The CaP@MSi powders
were synthesized by cationic surfactant-templating method. The effects of 10, 20, and 30% CaP content in the CaP@MSi
powders on the molecular surface structure, the cytotoxicity against osteoblast cells in vitro, and the mineralization potential
in simulated body fluid were investigated. The CaP@MSi characterized by the highest mineralization potential (30% CaP
content) were used for DOX adsorption and pelletization process. The CaP which precipitated in the CaP@MSi composites
was characterized as calcium-deficient with the Ca:P molar ratio between 1.0 and 1.2. The cytotoxicity assays demonstrated that
the CaP content in MSi increases osteoblasts viability indicating the CaP@MSi (30% CaP content) as the most biocompatible.
The combination of CaP and MSi was an effective strategy to improve the mineralization potential of parent material. Upon
immersion in simulated body fluid, the CaP of composite converted into the bone-like apatite. The obtained pellets preserved the
mineralization potential of CaP@MSi and provided the prolonged 5-day DOX release. The obtained biphasic CaP@MSi
composites seem to have an application potential as bone-specific drug delivery system.
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Introduction
The infection of bone (osteomyelitis) belongs to diseases dif-
ficult to diagnose and treat. Chronic osteomyelitis caused by
bacterial bone infections occurs mainly in adults, usually as a
consequence of open bone injuries, bone reconstruction, or
implant insertion. In clinical practice, the osteomyelitis is treat-
ed surgically with the simultaneous implementation of the
parenteral antibiotic therapy [1]. The main problem of the
antibiotic therapy is low bioavailability of drugs in bones
and thus inadequate therapeutic concentration of the antibi-
otics in infected area [2]. Therefore, increased attention has
been paid to local bone drug delivery systems with prolonged
antibiotic release tomaintain the drug concentration at suitable
level in bone tissue for the entire period of treatment [3, 4].
Another promising feature of such bone drug delivery systems
is mineralization potential connected with self-formation of
biological calcium phosphate on their surface which supports
the bone regeneration [5].
The combined effect of the high drug loading capacity of
mesoporous silica materials (MSi) for antibiotic delivery to-
gether with mineralization potential of calcium phosphate
minerals (CaP) is an outstanding perspective for bone therapy
purposes. The CaP are widely used in medicine and dentistry
because of their excellent biocompatibility and bioactive prop-
erties [6]. In the context of bone regeneration, CaP have been
used in various forms, ranging from amorphous calcium phos-
phate to crystalline hydroxyapatite (Hap) [7].
The MSi have been recently suggested as candidates for
bone drug carriers due to their mesoporous arrangement,
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specific surface area, chemical composition, and biocompati-
bility. However, the MSi materials have generally poor min-
eralization potential studied in simulated body fluid. The typ-
ical induction times for Hap nucleation on the surface of MSi
are in the range of 30–60 days [8]. To improve mineralization
potential of MSi, the osteogenic compounds were embedded
into the silica network [9, 10]. After addition of osteogenic
compounds, semi-crystalline carbonate apatite formation with
composition and morphology similar to bone apatite was ob-
served on silica surface. Unfortunately, the modification of
MSi materials with osteogenic ions results in disruption of
their ordered porous structure; consequently, reproducible
and effective drug adsorption is limited. Therefore, it is be-
lieved that the combination of the two components of CaP and
MSi might give a better result. This biphasic composite of
calcium phosphate-based mesoporous silica material
(CaP@MSi) can act as a bifunctional drug delivery system
with mineralization potential and prolonged drug release.
However, it is worth mentioning that the MSi materials ob-
tained via templating method exist in the form of powders
characterized by the relatively good adhesive properties and
low bulk density what causes problems in their direct pharma-
ceutical usage. Moreover, the fast release of water-soluble
drug in a burst stage has been frequently observed for drug-
loaded MSi. One of the difficulties with burst release is its
unpredictable nature. Additionally, the released amount of
drug during burst stage is hard to be significantly controlled
[11]. Nowadays, one of the most common strategies overcom-
ing the aforementioned disadvantages is the synthesis of hier-
archically structured materials in the nanoscale based on the
MSi powders [12, 13]. However, the production of drug-
loaded silica nanoparticles requires advanced skills and tech-
nologies to provide crucial factors such as the stability of the
nanoparticles which tend to agglomerate; the suitable ratio of
drug release to nanoparticles biodegradation; and the stimuli-
controlled drug release, necessary for targeted drug delivery
systems. Herein, wewould like to propose a simple solution in
the macroscale basing on the pharmaceutical technology. We
used the pelletization technique to prepare spherical granules
composed of the CaP@MSi powders. The applied pelletiza-
tion process is based on wet granulation, extrusion, and
spheronization steps in which the fine powders and excipients
are finally converted into small, spherical units, which are
referred to as pellets. The form of pellets was chosen due to
its desirable properties such as improved mechanical resis-
tance, great flow properties, low susceptibility to dose dump-
ing, and regular shape suitable for further pharmaceutical
processing.
The idea of our studies is to design, synthesize, and evalu-
ate the application potential of CaP@MSi composite materials
in the form of spherical granules—pellets as implantable, bi-
functional bone drug delivery system. After surgical implan-
tation, such system might provide the prolonged drug release
directly in the infected bone tissue and support the bone re-
generation via formation of surface hydroxyapatite with mor-
phology and composition similar to human bone apatite.
Consequently, the first aim of the present paper was to
synthesize a new biphasic composite composed of mesopo-
rous silica materials (MSi) and calcium phosphate (CaP) using
a cationic surfactant as the structure-directing agent. The cat-
ionic surfactant, cetyltrimethylammonium bromide (CTAB),
is one of the most studied in the synthesis of both the MSi and
CaP materials. It forms spherical micelles with ∼ 2–3-nm di-
ameter when critical micelle concentration is exceeded (∼
1 mM in water at room temperature). The formed micelles
undergo sphere-to-rod transition above ∼ 250 mM [14]. The
biphasic composite of MSi@CaP was further formed in the
wet precipitation process onto the self-assembling rod-like
micelles of CTAB. After the synthesis of biphasic composites,
we described the Ca:P molar ratio of the CaP found in MSi as
a function of both the CaP precursors amount in synthesis and
the immersion time in simulated body fluid. Next, we studied
the toxicity against osteoblast cells. Finally, we prepared
spherical granules (pellets) based on the optimal formulation
of biphasic composite of CaP@MSi with adsorbed drug and
excipients. Doxycycline hydrochloride (DOX) was chosen as
a model drug. It is highly water soluble antibiotic widely used
in the pharmacological treatment of osteomyelitis [15]. The
mineralization potential of the pellets and the DOX release
studies were investigated to show their potential in two bio-
medical applications: bone tissue regeneration and local drug
delivery.
Materials and methods
In situ synthesis of the composite CaP@MSi
The parent MSi powders (100MSi) were synthesized using a
surfactant templating method with tetraethyl orthosilicate
(TEOS, 98%, Gelest) as a silica oxide source and cationic sur-
factant N-cetyltrimethylammonium bromide (CTAB,
CH3(CH2)15N(CH3)3Br, 99.0%, Sigma-Aldrich) as a template.
The pure CaP (100CaP) were synthesized by following the same
templating method as for the 100MSi, where anhydrous calcium
chloride (CaCl2, 99.0%, Sigma-Aldrich) was used as a calcium
source and anhydrous di-potassium hydrogen phosphate
(K2HPO4, 99%, Sigma-Aldrich) as a phosphorous source and
CTAB as a template. The amounts of CaCl2 and K2HPO4 were
adopted to the chemical reaction (Eq. 1), following the wet syn-
thesis of Hap in the presence of ammonia [16]:
10CaCl2 þ 6K2HPO4 þ 2H2O→Ca10 PO4ð Þ6 OHð Þ2
þ 12KClþ 8HCl ð1Þ
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The composites ofMSi with CaP (CaP@MSi) were obtain-
ed by combining together the MSi and CaP precursors in
different proportions: amounts of precursors in the synthesis
of CaP@MSi are shown in Table 1. In brief, 125 g of water,
12.5 g of ethanol (> 99%, Sigma-Aldrich), 9.18 g of aqueous
ammonia (25 wt% in water, Sigma-Aldrich), and 2.39 g of
template (CTAB) were stirred together in polypropylene bea-
ker on magnetic stirrer (300 rpm) for approx. 15 min at room
temperature until the homogenous solution appeared. The pH
of the obtained solution was 10. Then, the relevant amounts of
K2HPO4, CaCl2, and TEOS (Table 1) were added and the
resulting mixture was continuously stirred for 2 h. Next, the
hydrothermal treatment of the mixture was carried out at 90
°C for 5 days without stirring. The resulting solid product was
recovered by vacuum filtration, washed with 100 ml of abso-
lute ethanol, and dried at 40 °C for 1 h. The CTAB template
was removed from the solid product using calcination in air
for a period of 6 h at 550 °C (heating rate of 1 °C/min) in a
muffle furnace (M-525, II series). The final CaP@MSi sam-
ples in the form of powders were micronized in grinder
(Mortar Grinder Pulverisette 2, Fritsch) for 10 min at 50
rpm. The 200–500-μm fraction was used for further studies.
The final compositions have been named as 100%MSi,
10%CaP@MSi, 20%CaP@MSi, 30%CaP@MSi, and
100%CaP taking into the account the theoretical amount of
Ca and P precursors used in the synthesis (Table 1).
Characterization of CaP@MSi
The molecular structure of as-synthesized CaP@MSi samples
was characterized using a Fourier transform infrared spectros-
copy (FTIR, Jasco model 410, 4 cm−1 resolution), using the
potassium bromide (KBr) disk technique. The parent 100MSi,
100CaP, and commercial crystalline hydroxyapatite (Hap;
Ca10(PO4)6(OH)2) powder (> 98%, Sigma-Aldrich) were also
studied for the comparative purposes. For better comparison
of synthesized materials, the FTIR spectra were normalized to
maximum absorption of dominant peak at ∼ 1080 cm−1 attrib-
uted to the asymmetric stretching of siloxane bands. The crys-
talline phases in the CaP@MSi were characterized by the
wide-angle powder X-ray diffraction (PXRD). PXRD analy-
ses were taken with an Empyrean/PANalytical XRPD diffrac-
tometer using CuKα1 radiation, operating at 20 kV and 40
mA. The samples were scanned from 10 to 60 in 2θ with a
scan speed of 2.0°/min. Joint Committee on Powder
Diffraction Standards (JCPDS) files were used to compare
the positions of diffracted planes.
The morphology and particle size of synthesized materials
were measured by using the scanning electron microscopy
(SEM). The Ca:P molar ratio values were determined accord-
ing to the data collected from different parts of the samples
using the energy dispersive X-ray spectroscopy (EDX). SEM-
EDX measurements were obtained on a Quanta 3D FEG and
Hitachi SU-70 electron microscopes at an acceleration voltage
in the range of 3–30 kV. Samples for SEM-EDXwere fixed on
carbon tape and coated with gold for 1 min. Transmission
electron microscopy (TEM) images were obtained using a
Tecnai G2 T20 X-TWIN electron microscope at an accelerat-
ing voltage of 200 kV. The samples were dispersed in hexane
over copper grids and dried in the air.
The porosity of the synthesized materials was determined
using nitrogen sorption experiments. The adsorption/
desorption isotherms of nitrogen at 77 K were measured with
an automated apparatus ASAP 2020 (Micromeritics, USA).
Prior to the measurements, the samples were degassed for 2 h
at 160 °C. The specific surface area was calculated with a
multipoint Brunauer–Emmett–Teller (BET) method. Total
pore volume was derived from the amount of adsorbed nitro-
gen at a relative pressure of p/po = 0.99. The pore size distri-
bution was determined from the adsorption branch of the iso-
therm by using the Barrett–Joyner–Halenda (BJH) method.
In vitro mineralization assay of CaP@MSi
The mineralization potential of the CaP@MSi composites
(200–500-μm particles size) was investigated using simulated
body fluid proposed by Kokubo and Takadama [17]. To pre-
pare 1 L of SBF, 7.996 g of NaCl, 0.350 g of NaHCO3,
0.224 g of KCl, 0.228 g of K2HPO4·3H2O, and 0.305 g of
MgCl2·6H2O were dissolved in 750 mL of deionized water.
Then, 39.0 mL of hydrochloric acid (1 M) was added to the
solution. Next, 0.278 g of CaCl2, 0.071 g of Na2SO4, and
6.057 g of TRIS were sequentially dissolved in the solution.
Finally, the solution was adjusted to pH = 7.4 with 1 M hy-
drochloric acid and diluted to 1 L using purified water. SBF
precursors were used as received from Sigma-Aldrich.
In order to investigate the mineralization potential of the
CaP@MSi composites, samples were immersed for 28 days in
simulated body fluids (SBF) using 1 mg of composite per 1
mL of SBF. Briefly, 100 mg of composite was immersed in
Table 1 Nominal compositions (wt%) and amounts of reactants (g) of
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100 mL of SBF in polypropylene forms. The experiment was
performed in water bath (WitegWSB-30) at 37.0 °C under the
stirring conditions (70 rpm). After every 24 h, the samples
were centrifuged, the supernatant was collected using pipette,
and the fresh portion of the SBF was poured [18]. After each 7
days of mineralization assay, the samples were filtered, dried
at 40 °C, weighted and investigated by using SEM-EDX
method in order to determine the Ca:P molar ratio and the
morphological structure of the samples. Next, the whole pro-
cedure was repeated providing 1 mg:1 mL ratio between ma-
terials and SBF.
In vitro cytotoxicity assay of CaP@MSi
Human fetal osteoblastic cell line (hFOB 1.19) was obtained
from American Type Culture Collection (cat. no. CRL-
11372™). Cells were cultured in 1:1 mixture of Ham/s F12
Medium Dulbecco’s Modified Eagle’s Medium, with 2.5 mM
L-glutamine (without phenol red) (Sigma-Aldrich), 15 mM
HEPES, and sodium bicarbonate, supplemented with 10% fetal
bovine serum and penicillin/streptomycin (100 U/mL/100 μg/
mL) at 34 °C in a humidified atmosphere of 5% CO2. Medium
was replaced every 2–3 days. Cells were passaged for a max-
imum of 3–4 months post resuscitation and regularly tested for
mycoplasma contamination by two methods: DNA staining
with 4,6-diamidino-2-phenylindoledihydrochloride (DAPI)
and MycoAlert Mycoplasma Detection Kit (Lonza, Basel,
Switzerland). The influence of parent 100MSi, 10CaP@MSi,
20CaP@MSi, 30CaP@MSi composites (200–500-μm particle
size) on osteoblasts viability was evaluated by 2D collagen gel
test (Collagen I, Rat tail, Sigma-Aldrich). The commercial hy-
droxyapatite (Hap) was tested for comparative purposes.
Before the assays, all tested materials were sterilized by heating
in air for a period of 3 h at 300 °C in amuffle furnace (M-525, II
series). Each material was suspended in collagen solution at
three tested concentrations: 10, 100 μg/mL, and 1mg/mL, then
vortexed, alkalized, and applied into each well of 48 well plate
in the volume of 150 μL for gelation. After 30 min of incuba-
tion at 37 °C, osteoblasts were seeded at 2.5 × 104 cells on
collagen gels in eachwell and incubated for 72 h. Cells cultured
onto collagen gel without suspended material was studied as a
control. Fluorogenic esterase substrate, BCECF-AM, was used
for visualization and quantitative evaluation of viable cells.
This ester is passively loaded into viable cells, and converted
by intracellular esterases into fluorescent products. BCECF-
AM staining was performed according to the standard protocol.
Images were obtained with a Axiovert 200 microscope
equipped with AxioCam MRm digital camera (Zeiss,
Thornwood, NY). For quantitative evaluation of cells viability,
fluorescence was measured with excitation/emission at 439/
535 nm using Synergy H1 microplate reader (BioTek,
Winooski, VT). For fluorescence-based quantification, fluores-
cence at 535 nm for the background (collagen gel with
suspended material and culture medium without cells) was
subtracted from each cell sample.
Data was presented as the mean ± standard deviations for
three independent experiments. Statistical analysis was per-
formed by Student’s t test using STATISTICA 13.3 software
(Statsoft, Poland). The results were considered to be statisti-
cally significant when p value was < 0.05 vs control.
Formulation of drug delivery systems
The optimal CaP@MSi composite characterized by the
highest mineralization potential and relatively low cytotoxic-
ity against osteoblasts was used for drug adsorption and pel-
letization process.
For the drug-loading experiment, the doxycycline hydro-
chloride (DOX, Sigma-Aldrich) was used as the model, water
soluble antibiotic. For the drug-loading experiment, the im-
mersion procedure was applied as described in our previous
reports [19, 20]. Briefly, DOX was first dissolved in purified
water (10 mg/mL). The optimal composition of CaP@MSi
(200–500 μm particle size) was then added to the solution
and the suspension was stirred for at least 2 h at 25 ± 0.5 °C
(protected from light) to ensure the equilibrium adsorption
state. Each 500 mg of CaP@MSi powders was suspended in
10 mL of DOX solution. The suspension was next filtrated
under vacuum and the concentration of the DOX remaining in
the solution was examined spectrophotometrically by moni-
toring the changes in absorbance at 347 nm—DOX analytical
wavelength in aqueous medium (UV-Vis spectrophotometer
Shimadzu, model UV-1800). The DOX-loaded CaP@MSi
composites (DOX-CaP@MSi) were dried at room tempera-
ture for 24 h. The amount of DOX adsorbed onto the
CaP@MSi composite and adsorption efficiency were calcu-








where Qe (mg/g) is an amount of DOX adsorbed at the equi-
librium state, %Ads (%) is an adsorption efficiency, C0 (mg/
mL) is an initial DOX concentration, Ce (mg/mL) is DOX
concentration at equilibrium state, V (mL) is a volume of
DOX solution, and m (g) is the mass of CaP@MSi composite.
The mean adsorption efficiency with standard deviation were
also calculated.
The pellets based on the DOX-CaP@MSi composite were
prepared by the wet granulation, extrusion, and spheronization
technique using Caleva Multi Lab apparatus. Based on the
preliminary studies, the pellets with both the satisfactory me-
chanical properties and 50 wt% of calcium phosphate-
mesoporous silica composite were obtained using the
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composition given below. The CaP@MSi and DOX-
CaP@MSi were used in ratio of 38 and 12 wt%, respectively.
The 12 wt% of DOX-CaP@MSi in the formulation
corresponded to the 2 wt% content of drug similar to drug
content in commercially available spherical granules (0.5–5
wt%) [21, 22]. The microcrystalline cellulose (MCC; Avicel
PH 101, Sigma-Aldrich) and ethyl cellulose (EC; Ethocel 20
cP, Dow Chemical) were used as the excipients (45 and 5
wt%, respectively). The batch size of each batch was 5 g.
Briefly 1.90, 0.60, 2.25, and 0.25 g of CaP@MSi, DOX-
CaP@MSi, MCC, and EC were used, respectively. The
0.60 g of DOX-CaP@MSi corresponded to 100 mg of DOX
providing 2 wt% drug content in the formulation. Powders
were accurately weighed, premixed in a mortar, and homoge-
neously mixed in a granulator attachment (100 rpm, 5 min)
and then mass was wet-agglomerated using EC ethanolic
binder solution (5 wt%) in the same attachment (100 rpm, 5
min). The optimal volume of binder solution, necessary for
granulation, was determined in preliminary studies using
Caleva Torque Rheometer. The wet mass was then extruded
in an extruder attachment running at 100 rpmwith a circular 1-
mm holes diameter and depth. The entire batch of extrudate
was then spheronized in a spheronizer attachment of diameter
8.5 cm (2000 rpm, 5min). The resultant pellets were left to dry
overnight at ambient conditions. The mean yield of the pellet-
ization process (calculated as the ratio of total weight of dried
pellets to initial weight of all usedmaterials) was 80 ± 2%. For
further studies (drug release and mineralization potential stud-
ies), the main fraction of pellets (0.8–1.0 mm) was chosen as
the fraction obtained from sieving with the highest weight (≥
90%). The actual amount of DOX in the pellets was deter-
mined by crushing the main fraction of the pellets and immer-
sion in purified water with vigorous shaking (500 rpm, 24 h,
room temperature) providing sink conditions. The total
amount of DOX released from main fraction of the pellets
was examined spectrophotometrically (by monitoring the
changes in absorbance at 347 nm). The procedure was repeat-
ed for 3 batches.
Release studies of DOX-CaP@MSi pellets
The drug release studies were performed using USP II Paddle
Apparatus (Copley DIS-6000) at 37.0 °C, 50 rpm. Briefly, the
3.8 g of the pellets, 0.8–1.0 mm fraction (equivalent to 72 mg
of adsorbed DOX) was used in each test. A constant fraction
of the pellets was used for each batch in order to minimize the
effect of the change in total surface area of the pellets on the
drug dissolution rate. Phosphate buffer (pH = 7.4; 500 mL)
was used as the dissolution media providing sink conditions.
At suitable time intervals, 2.0 mL of solutions was filtered
using membrane filters (0.22 μm) and analyzed spectrophoto-
metrically at 352 nm—DOX analytical wavelength in phos-
phate buffer medium. Analytical studies were conducted in
accordance with the requirements for quantitative analyses,
calibrating the detector with a standard solution of the tested
DOX in buffer. The drug stability was provided during the
whole release studies. Drug release data were plotted as the
cumulative percent of DOX released (Q) as a function of time
(t). The release studies were repeated 6 times. The same re-
lease studies were carried out for pristine DOX-CaP@MSi
powders (with 72 mg of adsorbed DOX) for comparative
purposes.
In vitro mineralization assay of DOX-CaP@MSi pellets
The mineralization potential studies of DOX-CaP@MSi pel-
lets were carried out following similar procedure as described
for CaP@MSi composites, except that 2 mg of pellets was
used for each 1 mL of SBF. The SEM-EDX analysis was
carried out for pellets before and after every 7 days of incuba-
tion in SBF. The SBF was exchanged every 24 h in accor-
dance with reference [18]. Due to the sedimentation of the
pellets, the SBFwas exchanged by simple decantation method
instead of centrifugation which was performed for CaP@MSi
powders.
Results and Discussion
This study is part of our ongoing effort to evaluate the ability
of hexagonally ordered mesoporous silica, MSi, for two bio-
medical applications: local antibacterial drug delivery and
bone tissue regeneration. We synthesized the biphasic com-
posites of CaP with MSi to improve mineralization properties
of parent 100MSi. Rim et al. [13] have already combined the
CaP and the MSi developing absorbable, pH-tunable calcium
phosphate covered MSi nanocontainers for intracellular con-
trolled release of doxorubicin. They have emphasized that
CaP is widely used as a bioactive osteoconductive coating
for bone-regenerative materials which is formed after immer-
sion of the material in SBF. They have used the CaP coating as
pore blocker of drug-loaded MSi nanoparticles. Such coating
may be dissolved in acidic cellular environments to provide
the release of entrapped doxorubicin directly in the target tu-
mor cells. In our case, we would like to obtain the CaP@MSi
composites in the form of 1 mm spherical granules—pellets
which after implantation during the surgery may act as bifunc-
tional, local bone drug delivery system: (i) releasing the drug
directly in the infected area and (ii) regenerating the bone
defects.
In the unpublished results, we performed pre-optimized
selection studies with different amounts of CaP in MSi (up
to 50%) to find optimal CaP@MSi composition. We were
taking into account 3 parameters of obtained composites: po-
rosity, adsorption process of DOX (both the adsorption effi-
ciency and repeatability), and mineralization potential. We
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found that the addition of CaP higher than 30% resulted in
disordering of the MSi@CaP structure. The disordering of
MSi@CaP structure caused the unrepeatable and also relative-
ly low adsorption of DOX. The reason of observed
disordering is the consequence of the precipitation of calcium
phosphates particles and their aggregation in the mesoporous
silica network. These all heterogeneous CaP-rich regions may
induce local network deformations responsible for a decrease
in bulk porosity of the MSi@CaP. Moreover, in the mineral-
ization studies, we also found that the rate of mineralization
for composites with CaP above 30% was not significantly
higher compared to 30CaP@MSi. Moreover, those compos-
ites containing higher than 40% of CaP showed tendency to
phase separation. These formulations had been easily
disintegrated in the distal portion of small particles in simulat-
ed body fluid.
In the next step of studies, we selected the formulation of
CaP@MSi characterized by highest mineralization potential
to load the model antibiotic—doxycycline (DOX) by adsorp-
tion process and prepare drug delivery system in the form of
spherical granules (pellets) considering the cytotoxicity values
of CaP@MSi composites. During the pelletization process,
we used only these pharmacopeial excipients which are
known to be non-toxic and biocompatible [23, 24].
Characterization of synthesized CaP@MSi
The detailed FTIR spectra of the as-synthesized CaP@MSi
composites are available in Supplementary material 1. The
FTIR results confirmed both the successful removal of
CTAB during the calcination process and the presence of
phosphate groups in the composites after synthesis. Figure 1
shows the comparison of FTIR spectra between a commercial
hydroxyapatite (Hap) and as-synthesized 100CaP, parent
100MSi, and CaP@MSi samples. The FTIR spectra for Hap
and 100CaP were almost the same, only the new peak at 867
cm−1 (ν2) of carbonate group was observed in the 100CaP
sample. This band was not clearly distinguished for the
CaP@MSi composites and it could also overlap together with
a Si-O-Si stretching mode at 800 cm−1 from the MSi. In the
Hap and 100CaP spectra, the peaks at 603 cm−1 and 564 cm−1
were assigned to (PO4)
3- groups with vibrational mode of ν4
whereas the peaks at 1090, 1032, and 961 cm−1 were charac-
teristic for the ν3, ν3, and ν1 vibrational modes of (PO4)
3-,
respectively [25]. The peaks at 603 cm−1 and 564 cm−1 proved
that the CaP phase in CaP@MSi composites was successfully
formed during the templating method: with the increase of
CaP in MSi the intensities of 603 cm−1 and 564 cm−1 peaks
increased. For the FTIR spectrum of composite with the larg-
est amount of CaP (30CaP@MSi), the 1090 cm−1 was also
observed. Figure 2 shows the PXRD patterns of the pure
100CaP, parent 100MSi, and CaP@MSi composites
(10CaP@MSi, 20CaP@MSi, 30CaP@MSi). The typical
broad diffraction halo was observed for the parent 100MSi.
In contrast, phase analysis showed that all major peaks of
hydroxyapatite were present in the as-synthesized pure
100CaP. The presence of low crystalline apatite (Ca3(PO4)2·
H2O), typical hydrated calcium phosphate phase, was also
observed in the XRD patterns of the 100CaP. This result has
been also identified by other authors that used the wet precip-
itation method for the CaP synthesis [26]. In the all CaP@MSi
composites, the amorphous halo characteristic for the parent
100MSi phase was observed. The CaP identification in the
CaP@MSi composites was based on the presence of a diffrac-
tion peak at 2θ = 26° and a broad diffraction feature in the
region of 2θ = 31–34°. The lowest intensity of these peaks
was observed for 10CaP@MSi and with the increase of CaP
in MSi the doublet of diffraction peaks at 2θ = 31° became
partially resolved. These diffraction peaks could also indicate
the presence of low crystalline calcium phosphate mineral in
the CaP@MSi composites compared to the as-synthesized
100CaP. The results indicated that the crystallinity of CaP
was reduced with increasing content of MSi in composite,
indicating thatMSi could cause alteration of the CaP structure.
This suggests that MSi could control the particle dimension of
CaP particles and could prevent the aggregation as well as the
crystallization of CaP. This might be attributed to the molec-
ular motion and interfacial kinetics which limit the growth of
crystal and therefore the crystallite size of CaP at the presence
of MSi. It was also confirmed by SEM analysis. Figure 3
shows the SEM images with the representative EDX profile
of the morphology of pure 100CaP and parent 100MSi.
Supplementary material 2 shows the TEM image of represen-
tative particle of 100CaP and 100MSi. For the 100CaP, the
homogenous rode-like structures were obtained. For the par-
ent 100MSi, the homogenous surface of spherical particles
was observed. The measured average particle size of
100CaP and 100MSi was 370 ± 50 nm and 100 ± 12 nm,
respectively (Supplementary material 2). Figure 4 shows the
SEM images with the representative EDX profile and map-
ping of CaP@MSi composites (10CaP@MSi, 20CaP@MSi,
30CaP@MSi). For the 10CaP@MSi, and 20CaP@MSi, the
spherical-shaped phase was still observed with tendency to
agglomeration that led to the larger particle size for
20CaP@MSi. Whereas for 30CaP@MSi, the elongated, rod-
like-shaped structure was observed. The smallest spherical
particles of CaP precipitated in MSi (average particle size
was 20 ± 8 nm) were obtained for the lowest (10%) content
of CaP in MSi, whereas the largest rod-like-shaped particles
(average particle size was 47 ± 14 nm) were obtained for the
largest (30%) content of CaP in MSi. This was also confirmed
by TEM results (Supplementary material 2). The representa-
tive TEM images of 30CaP@MSi and parent 100MSi evi-
dently indicated the biphasic structure of some rod-like elon-
gated particles embedded in the ordered hexagonal structure
of MSi. A study done by Santos et al. [27] has shown that
Drug Deliv. and Transl. Res.
precipitated Hap particles can be characterized by different
shapes such as long columns, thick-like plates, and needle-
like rods if the precipitation reaction is carried out at alkaline
reactions by using Ca(OH)2 and H3PO4 as the starting
materials.
In summary, the microscopic and PXRD results have indicat-
ed that MSi can control the particle size of CaP phase and par-
tially prevent the aggregation aswell as the crystallization of CaP.
The N2 adsorption-desorption isotherms data confirmed these
observations as well. Supplementary material 3 shows the N2
adsorption-desorption isotherms (a) and the pore-size distribution
(b) with the summarized data of BET specific surface area, the
total pore volume and average pore diameter corresponding to
the pure 100CaP, parent 100MSi, and CaP@MSi composites
(10CaP@MSi, 20CaP@MSi, 30CaP@MSi). The N2 isotherms
of pure 100CaP showed a type IV with the H3-type hysteresis
characteristic for slits-shaped pores. This kind of pores has been
often observed for plate-like structure [28]. Both the BETsurface
area closed to 128 m2/g and the broad distribution of pores with
no clear peak in pore size distribution (Supplementarymaterial 3)
suggest almost the non-porous state of pure 100CaP. The N2
isotherms of parent 100MSi and 10CaP@MSi showed a type
IV with a reversible isotherm for MSi and H1-type hysteresis for
10CaP@MSi, corresponded to cylindrical mesopores [29]. For
the 20CaP@MSi and 30CaP@MSi, the adsorption isotherms
were characterized by two separated steps, corresponding to N2
condensation in the MSi (at low pressure) and in the CaP do-
mains (at high pressure). The broader distribution of pores with
smaller pore diameter for CaP@MSi composites compared to
the parent 100MSi indicated the heterogeneous nature of
CaP@MSi composites due to the existing of two phases—MSi
and CaP confirmed by SEM and TEM images (Fig. 4 and
Supplementary material 2). From the analysis of the porosity, it
could be claimed that pore diameter, pore volume, and specific
surface area were representative of the individual porosities of
both the 100CaP and parent 100MSi components. This means
that with an increase in the amount of CaP in MSi, the specific
surface area decreased by a factor of 3.0 (from 765 m2/g for the
Fig. 1 FTIR spectra of synthesised materials: 100CaP, 30CaP@MSi (a), 20CaP@MSi (b), 10CaP@MSi (c), 100MSi and hydroxyapatite reference
sample
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parent 100MSi to 250 m2/g for 30CaP@MSi), the total pore
volume decreased by a factor of 2.3 (from 0.54 to 0.23 cm3/g,
respectively) whereas the average pore diameter slightly in-
creased (from 28 Å to 37 Å, respectively).
According to the complementary results from FTIR,
PXRD, SEM, and nitrogen sorption analyses, it might be sum-
marized that spontaneous formation of biphasic CaP@MSi
composite is followed by two steps: (1) the dissolution of
Fig. 2 XRD patterns of synthesised materials: 100MSi, 10CaP@MSi, 20CaP@MSi, 30CaP@MSi, 100CaP and hydroxyapatite reference sample
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the K2HPO4, CaCl2, and TEOS at CTAB solution in ammonia
medium (pH = 10) and (2) the composite self-assembly on the
rod-like CTAB micelles. In details, the silanol anions of hy-
drolysed TEOS (SiO-) together with phosphate ions may neu-
tralize the positively charged ammonium groups of CTAB and
form CTAB+SiO- and CTAB+PO4
3-. These species can further
interact with the Ca2+ from CaCl2. After removing of CTAB,
the spherical-shaped SiO2 and plate-like-shaped CaP struc-
tures are produced and hence the biphasic composite structure
is formed. The different Ca:P molar ratios of the precipitated
CaP phases in MSi suggest that the MSi can effectively con-
trol both the particle size and the subsequent arrangement of
CaP particles. In case of 100CaP, the steric hindrance is low;
thus, the relatively large plate-like-shaped Hap was synthe-
sized followed by the spontaneous growing of the CaP nuclei.
With an increase in the MSi:CaP mass ratio, the number of
CaP which may interact with SiO2 around the CTAB micelles
decreases; hence, the additional steric hindrance is reinforced
and the smaller CaP nuclei will grow. Thus, smaller rod-like-
shaped CaP structures are observed in the presence of MSi.
In vitro mineralization assay of CaP@MSi
To investigate the mineralization potential of the biphasic
CaP@MSi composites, the representative samples of each
composites were immersed in simulated body fluid for 28
days with daily exchange of SBF. The changes in the Ca:P
rat ios of CaP@MSi composites are presented in
Supplementary material 4. After 7 days of incubation in
SBF, the Ca:P ratio of 1.67, close to natural bone apatite
Fig. 3 SEM-EDX micrographs of synthesised materials: 100MSi and 100CaP
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[30], was only observed for the 30CaP@MSi composite,
whereas the 20CaP@MSi and 10CaP@MSi composites re-
quired approx. 14 and 28 days, respectively. Figure 5 shows
the representative SEM-EDX results for 10CaP@MSi,
20CaP@MSi, 30CaP@MSi composites and 100MSi,
100CaP samples after 7 days of incubation in SBF. For
10CaP@MSi, the random clusters of calcium phosphates ap-
peared with Ca:P molar ratio of 1.35. For 20CaP@MSi, clus-
ters transformed into continuous agglomerates (Ca:P = 1.48).
SEM image showed that the surface of the 30CaP@MSi was
completely covered by a calcium phosphate species with mor-
phology characteristic for hydroxyapatite. The relatively
higher content of carbon in EDX of 30CaP@MSimay suggest
the incorporation of carbonates into hydroxyapatite structure.
Themechanism of formation of Hap on the CaP@MSimay be
related to the biomimetic behavior of CaP@MSi in simulated
body fluid comparable with bioactive properties of bioglass
[31]. A biomimetic apatite coating can grow on the CaP@MSi
surface by attachment of Ca2+ and PO4
3- ions from SBF.
However, it was found from SEM results that the surface
morphology of 100MSi and 100CaP did not change after 7
days of incubation in SBF. Moreover, 100MSi sample exhib-
ited the same EDX profiles before and after 7 days of miner-
alization assay, whereas for the 100CaP, the EDX results
shown that Ca/P ratio slightly changed from 1.5 to 1.6. The
lack of characteristic carbonated Hap semi-crystallites with
Ca/P ratio around 1.67 [32] on the surface of 100CaP sug-
gested that only some reorganization of the 100CaP structure
in simulated body fluid took place. This could suggest that the
100CaP obtained by the wet precipitation method did not react
with ions from the SBF, what was necessary to create a bio-
mimetic carbonated apatite [33] or the reaction would take
Fig. 5 SEM-EDX micrographs of 10CaP@MSi, 20CaP@MSi, 30CaP@MSi, 100MSi and 100CaP materials after 7 days of incubation in SBF
Fig. 4 SEM-EDXmicrographs of synthesisedmaterials: 10CaP@MSi, 20CaP@MSi, 30CaP@MSi with corresponding EDX-mapping: Si-blue, Ca-red,
P-green
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place in much slower manner compared to 30CaP@MSi. In
summary, from these results, the highest mineralization poten-
tial was observed for the 30CaP@MSi composite.
In vitro cytotoxicity of CaP@MSi
To establish an impact of tested materials on osteoblasts via-
bility, cells were exposed to collagen gel with suspended:
parent 100MSi, 10CaP@MSi, 20CaP@MSi, 30CaP@MSi
composites, and the commercial hydroxyapatite (Hap) (200–
500-μm particle size) at concentrations of 10, 100 μg/mL, and
1 mg/mL, respectively. The cells cultured on bare collagen gel
was used as control. There were no statistically significant
differences in the cells viability from particular materials at
lower concentrations (10 and 100 μg/mL) (results not shown).
The results obtained from 2D collagen gel test for the highest
concentration (1 mg/mL) were presented in Fig. 6(a). The
cells incubated with parent 100MSi spread less and took on
the spherical morphology indicating its low biocompatibility
(Fig. 6(b)). It probably results from the well-known high ad-
sorptive properties of mesoporous silica materials that can
contribute to adsorption of essential components of cell cul-
ture medium (e.g., amino acids, growth factors) [34, 35],
thereby weakening cell viability. On the other hand,
30CaP@MSi presented influence on the cell viability similar
to the commercial Hap with proven biocompatibility towards
osteoblasts [36]. Moreover, the viability of cells cultured on
collagen gel with suspended 30CaP@MSi increased twofold
in relation to control. The higher content of CaP in composite,
the better spreading, adhesion and more elongated, flattened
morphology of cells was presented (Fig. 6(b)). To conclude,
the results obtained from the 2D collagen gel test suggest that
the biocompatibility of CaP@MSi composites at higher con-
centration (1 mg/mL) seems to be positively correlated with
the tested CaP content in MSi composites. According to the
literature, calcium is a critical factor in osteoblast proliferation,
survival, differentiation, and mineralization [37, 38]; thus, the
observed correlation and high value of cell viability for
30CaP@MSi may be related to calcium release from compos-
ites into the cell culture medium.
Pellets based on the DOX-30CaP@MSi
Based on the presented mineralization potential studies and
the in vitro cytotoxicity tests, the 30CaP@MSi composite
was chosen for DOX adsorption and pelletization process be-
cause it was characterized by the highest mineralization po-
tential and low cytotoxic effect on the osteoblasts cells.
DOX adsorption onto the 30CaP@MSi
The adsorption efficiency was 84 ± 3% what corresponds to
165 ± 9 mg of DOX adsorbed per 1 g of 30CaP@MSi. The
high adsorption efficiency in the performed adsorption condi-
tions (pH = 3.5) might be explained by the favorable interac-
tions between amine group present in DOX molecules and
silanol groups present on the 30CaP@MSi composite surface.
At pH = 3.5, the amine group of DOX molecule exists in the
protonated form (R3NH
+; pKa = 9.7) [39] whereas the free
silanols (≡SiOH) of 30CaP@MSi are dissociated (≡SiO-; pKa
= 2.0) [40]. Thus, the ionic attraction between DOXmolecules
and 30CaP@MSi surface may occur. Additionally, the other
polar groups of the DOX molecule (phenolic, amide, carbon-
ylic) could interact with both the dissociated free silanols and
undissociated geminal silanols (=Si(OH)2, pKa = 8.0) [40] of
30CaP@MSi surface via hydrogen bonds, thus increasing the
adsorption efficiency. The drug adsorption onto the
30CaP@MSi was confirmed by FTIR (Supplementary
material 5) where the vibrations specific for DOX were being
observed in the ranges of 3000–2800, 1600–1100, and 950–
600 cm−1 for DOX-30CaP@MSi sample. The peaks charac-
teristic for the polar groups of the antibiotic were shifted to
Fig. 6 Evaluation of viability of osteoblasts grown onto collagen gels for 72 h with parent 100MSi, CaP@MSi, and commercial Hap (a); fluorescent
images of live osteoblasts (BCECF-AM) (b). The values presented are means ± SD (n = 3). *Statistically significant, p < 0.05 vs control
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lower frequencies respect to DOX reference spectrum what
confirmed the interactions between drug molecules and
30CaP@MSi surface.
Morphology of the DOX-30CaP@MSi pellets
DOX-30CaP@MSi pellets were successfully prepared by wet
granulation, extrusion, and spheronization method. The drug-
loaded pellets (Fig. 7) were found to be spherical with satis-
factory physical properties which allowed for further studies
(drug release and mineralization potential studies) without risk
of pellets cracking. As shown in Fig. 7, the pellets surface was
composed of continuous, organic regions made of microcrys-
talline and ethyl cellulose (relatively high carbon content ob-
served in EDX) and heterogeneous, inorganic regions made of
biphasic 30CaP@MSi composite. The presence of chloride in
EDX profile no. 2 (Fig. 7) derives from DOX molecules
adsorbed onto the 30CaP@MSi composite accordingly to
FTIR results (Supplementary material 5).
DOX release studies
Figure 8 shows the release profiles of DOX for both the DOX-
30CaP@MSi powders and pellets. The cumulative percent of
DOX released (Q) as a function of prolonged time (Fig. 8(a))
and initial 6-h burst release (Fig. 8(b)) are presented. A signif-
icant burst effect of the DOX release from the DOX-
30CaP@MSi powders was observed, about 90 ± 7% of
adsorbed drug was being released in the first 4 h of studies
(Fig. 8(b)) with complete drug release after 2 days (Fig. 8(a)).
In the case of DOX-30CaP@MSi pellets, the burst release was
reduced by a factor of 1.5, only 60 ± 4% of drug was released
after 4 h (Fig. 8(b)). For DOX-30CaP@MSi pellets, the drug
release was prolonged to 5 days.
For the DOX-30CaP@MSi powders, the high burst release
of DOX is observed most probably due to weak interaction
between DOX and silica surface. Similar observations for
DOX-loaded MSi were noticed by Deacuno et al. [41] who
declared, that initial burst release of DOX has been strongly
associated with the type of functional groups presented on
MSi surface. Ide et al. [42] claimed that the calcination pro-
cess of MSi results with the low concentration of surface
silanol groups. Therefore, low concentration of silanols im-
pedes the composite-DOX interactions (ionic, hydrogen
bonding) which are crucial for prolonged drug delivery sys-
tems [19, 20]. In case of DOX-30CaP@MSi powders, the
high burst release was also the result of DOX location (at least
in part) out of the pores what is characteristic for the per-
formed adsorption method (adsorption from concentrated so-
lution). The DOX fraction presents loosely on the external
silica surface dissolved immediately after immersion in re-
lease medium.
For the DOX-30CaP@MSi pellets, the reduction in DOX
burst release with simultaneous prolongation of total drug
release was achieved due to formation of spherical matrix
(pellets) insoluble in release medium with increased hydro-
phobicity because of using of ethyl cellulose as a filler and
binder. The release profile of DOX-30CaP@MSi pellets was
characterized by two stages (Fig. 8(a) and (b)): first stage—an
initial 50% release of loaded DOX in 1 h and second stage
with prolonged drug release during 5 days. Such two-stage
drug release profile of pellets seems to be a promising feature
in current strategies of osteomyelitis treatment which focuses
on both the reduction of systemic dosage and the increase of
the antibiotic concentration directly in bone tissue [43]. On the
one hand, the relatively high initial release of DOXduring first
24 h might be considered as a loading dose at the beginning of
the treatment. For example, Trizio et al. [44] obtained
gentamycin-loaded eumelanin nanoparticles as potential bone
drug delivery system in which the complete drug release was
observed after 24 h with high burst release (approx. 72% in 1
h). Shorter, 4-h complete drug release was reported by Dorati
Fig. 7 SEM-EDX micrograph of DOX-30CaP@MSi pellet
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et al. [45] who proposed gentamycin-loaded chitosan thermo-
setting hydrogels. In both publications, it has been claimed
that obtained systems in vitro could exhibit potential antibac-
terial effect in the first stage of osteomyelitis treatment, due to
the high local drug concentration provided in fast manner. On
the other hand, the prolonged 5-day release of DOX from
DOX-30CaP@MSi pellets might provide the maintaining
dose of drug at infected bone sites. Approx. 5-day release of
drugs was reported for both biodegradable and non-
biodegradable bone delivery systems loadedwith gentamycin,
fosfomycin, vancomycin, ceftazidime, and tobramycin prov-
ing their potential ability to support the systematic treatment
of osteomyelitis [46, 47]. Additionally, the complete drug re-
lease from proposed DOX-30CaP@MSi pellets is also an im-
portant feature of candidate for bone drug delivery system.
Inert carriers such as bone cements may result in long (> 30
days) but incomplete drug release, causing a persistent release
of sub-inhibitory concentrations of loaded antibiotics and in-
creases the risk of antibiotic resistance [48].
Drug release from a porous matrix involves the penetration
of release medium, drug dissolution, and leaching out of the
drug through system of channels and pores. Based on the
pharmaceutical technology of solid dosage forms [49, 50],
the polymer content (microcrystalline cellulose, ethyl cellu-
lose) increases both the matrix tortuosity and drug diffusion
path-length and thus slows down the drug diffusion rate and
release from the matrix. To prove these claims, the release
kinetics studies have been performed. For spherical particles
with a granular matrix containing a water soluble drug, the
release kinetics may be described using Kosmeyer-Peppas or
Higuchi models [20, 51]. Therefore, the release kinetic param-
eters for both the DOX-30CaP@MSi powders and pellets
were calculated using linearized forms of Korsmeyer–
Peppas and Higuchi models as presented in Eqs. 4 and 5,
respectively.
log Q ¼ n log t þ log k ð4Þ
Q ¼ kH t12 ð5Þ
where Q denotes the fraction released by time t (h), n is an
exponent related to the drug release mechanism, k (h−n) is a
rate constant, and kH is a Higuchi dissolution constant (h
-1/2).
In Eq. 4, n = 0.43 indicates a Fickian diffusion for spherical
particles, and n = 1 corresponds to zero-order release. To find
out the mechanism of drug release, the data for first 60% of
drug release fraction (Q) were fitted with both models.
The kinetic parameters of fitted experimental data for DOX
release with Korsmeyer-Peppas and Higuchi kinetic release
models are presented in Fig. 8(c) and (d), respectively. For
both the DOX-30CaP@MSi powders and pellets, the release
kinetics were well characterized by Korsmeyer-Peppas model
with R2 = 0.93 and 0.96, respectively (Fig. 8(c)). In case of
DOX-30CaP@MSi powders, the release profiles were char-
acterized by simple Fickian diffusion (n = 0.43), whereas for
DOX-30CaP@MSi pellets the n value was found to be 0.53.
The observed increase in n value (from 0.43 to 0.53) suggests
the deviations in simple diffusion for DOX release from the
pellets. If a dissolution medium penetrates into the pellets,
then structural swelling, stress fields or matrix erosion may
affect diffusion. The partial erosion/swelling of the pellets
Fig. 8 Release profiles of DOX-30@CaP@MSi powders (blue) and pel-
lets (red): total drug release profile (a); first 6 h of drug release (b);
Korsmeyer-Peppas model (c); Higuchi model (d). The values presented
are means ± SD (n=3); n–release exponent in Korsmeyer-Peppas model,
kH–Higuchi dissolution constant (h
-1/2), R2–coefficient of determination
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surface was also observed in SEM micrographs after drug
release (Supplementary material 6). It is noteworthy, that the
pellets matrix may also act as a hydrophobic boundary that
impedes the access of solvent to drug molecules inside the
matrix. Such boundary in case of DOX-30CaP@MSi powders
is extremely lower and limited only to wall thickness of meso-
porous silica material.
The drug release for both the DOX-30CaP@MSi powders
and pellets was characterized by the profile less consistent
with the Higuchi (R2 = 0.89 and 0.93, respectively) (Fig.
8(d)). For the DOX-30CaP@MSi powders, it is caused most
probably by the DOX fraction present on the externally silica
surface. This fraction dissolved rapidly after exposure to sol-
vent. In case of DOX-30CaP@MSi pellets, the deviations
from Higuchi model may be a consequence of the importance
of excipient properties.While a pellets matrix is partially erod-
ing or swelling, Eq. 5 should not be developed with stationary
boundary conditions. However, the release kinetics for the
DOX-30CaP@MSi pellets was characterized by relatively
lower values of Higuchi dissolution constant (kH = 67.9)
(Fig. 8(d)) in comparison with DOX-30CaP@MSi powders
(kH = 95.3), indicating reduced burst release of DOX, what is
in good correlation with experimental release profiles (Fig.
8(b)).
In vitro mineralization of DOX-30CaP@MSi pellets
Themorphological changes of DOX-30CaP@MSi pellets sur-
face before and after 14 and 28 days of incubation in SBF are
presented in Fig. 9. There was no significant difference be-
tween the pellet morphology before and after 7 days of
mineralization assay (data not shown) what might be connect-
ed with both the drug release and the presence of excipients
which impede the hydroxyapatite formation. After 14 days of
mineralization assay, the new spherical particles with sizes in
about 10–20 μm in diameter were formed on the pellets sur-
face. After further 14 days of pellets incubation in SBF (28
days in total), the spherical particles formed closely to each
other and reorganized into the continuous layer. Based on both
the results obtained for powders and our previous reports [19,
20], the randomly formed clusters which spread over the pel-
lets surface are characteristic for carbonate hydroxyapatite.
Furthermore, the hydroxyapatite clusters changed their mor-
phology after 28 days of immersion in SBF into porous,
spongy-like one. Suchmorphology is characteristic for human
cancellous bone [52]. The progressive formation of carbonate
hydroxyapatite was also confirmed by EDX (Fig. 9) where the
increased Ca:P molar ratio had been observed every 14 days
of mineralization potential studies (from 1.23 to 1.71). The
1.71 Ca:P molar ratio and the presence of sodium, magne-
sium, carbonate and chloride ions in hydroxyapatite structure
after 28 days of mineralization assay suggest that such com-
position is similar to composition of biological bone apatite
[30].
Conclusion
The combined effect of the mineralization potential of CaP
minerals together with the high capacity drug loading of
MSi for drug delivery is an outstanding perspective for bone
therapy purposes. The rod-like-shaped CaP and spherical-
Fig. 9 SEM-EDX micrographs of DOX-30CaPMSi pellets before and after 14, 28 days of mineralization assay in SBF
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shaped SiO2 structures successfully formed biphasic
CaP@MSi composites structure with the low crystalline CaP
phase by using wet precipitation method. The 30%CaP addi-
tion during the synthesis resulted in composites with the
highest both mineralization potential in vitro, osteoblast bio-
compatibility, and successful drug loading.
The obtained pellets as proposed final form of the
doxycycline-loaded composites allowed to complete 5-day
release of drug with two-stage release profile which imitates
the initial and maintenance doses of released drug. Such pel-
lets may represent a novel solution in development of
prolonged release bone drug delivery systems supporting the
pharmacological treatment of osteomyelitis. After implanta-
tion, such system may provide the biphasic drug release in
order to lower the doses of parenterally administrated antibi-
otics, thus reducing both the possible adverse effects and risk
of antibiotic resistance. Additionally, obtained system seems
to support the bone regeneration via surface hydroxyapatite
formation. Extension of the presented experiments to antimi-
crobial activity of obtained formulations is in progress and
will be reported in due course.
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